The effect of body weight on sarilumab pharmacokinetics is consistent with clinical efficacy findings, which showed a trend for lower American College of Rheumatology 20% improvement criteria response rates for sarilumab vs. placebo at 150 mg q2w in patients weighing ≥ 100 kg vs. those weighing 60 to < 100 kg [ 14 ].
← all excerpts
Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis.
1
—
—